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CMT1A is the most common inherited peripheral neuropathy. There is currently no approved treatment. We performed a
meta-analysis including four randomized, double-blind, Placebo-controlled clinical trials to assess the disease progression
after one year under Placebo, Ascorbic Acid (AA) or PXT3003, a combination of three repurposed drugs. We observed a
weak deterioration in patients under Placebo, well below the reported natural disease progression. Patients treated with
AA were stable after one year but not significantly different from Placebo. Patients undergoing PXT3003 treatment
showed an improvement in CMTNS and ONLS, statistically significant versus Placebo and potentially precursory of a
meaningful change in the disease course.
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Charcot-Marie-Tooth disease Type 1A (CMT1A, OMIM:
118220, Orphanet: ORPHA101081) is a rare, inherited,
peripheral neuropathy caused by duplication of the gene
PMP22 [1, 2], whose over-expression induces dysmyelina-
tion, axonal loss and muscle wasting [3, 4]. Two
treatments have been recently investigated in seven 1- or
2-year randomized, double blind, placebo-controlled clin-
ical trials: Ascorbic Acid (AA) [5–12] and PXT3003, a
combination of (RS)-baclofen, naltrexone hydrochloride
and D-sorbitol [13, 14]. Now that all these trials have been
completed, and as recommended at the 168th ENMC
international workshop [15], we report the results of a first
meta-analysis assessing the disease progression after one
year under Placebo, AA or PXT3003.* Correspondence: jmandel@pharnext.com
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We conducted a literature search through PubMed and
ClinicalTrials.gov for randomized, placebo-controlled
clinical trials lasting 12 months or more using ‘‘Charcot-
Marie-Tooth type 1A disease’’ and its synonyms’ ‘‘heredi-
tary motor and sensory neuropathy’’, ‘‘peroneal muscular
atrophy’’ and ‘‘distal spinal muscular atrophy’’ as the
search terms. MEDLINE search terms are given in
Appendix. We also checked the bibliography of identified
trials. The outcomes of interest were the change from
baseline in CMTNS [16] and ONLS [17] after one year of
treatment or Placebo, hence only trials measuring
CMTNS or ONLS were selected. CMTNS and ONLS are
considered as the main clinical scales for impairment and
disability, respectively, in CMT1A disease [15]. Studies
measuring at least one of these two outcomes were se-
lected. In both measures, an increasing score is considered
as deterioration.
The estimated mean changes from baseline and corre-
sponding standard errors were extracted from the publica-
tions. When not available, standard errors were deducedrticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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information were excluded from the meta-analysis.
For each outcome, we performed fixed and DerSimonian-
Laird random effects meta-analyses including treatment
(Placebo, AA or PXT3003) as moderator factor. The Q-
test and I2 index were used to determine the level of het-
erogeneity in the random effect model. Comparisons of
AA and PXT3003 versus Placebo were performed with
tests of contrast of the moderator factor.
Results
Four studies met the inclusion criteria: three on AA [10–12]
and one on PXT3003 [14]. For the PXT3003 trial, only
the dose showing a significant effect was considered,
i.e. the highest dose tested termed ‘PXT3003 HD’. For
ONLS in the Pareyson study, values at 24 months were
used as values at 12 months were not available. In total,
565 patients were included in these trials: 220 with Pla-
cebo, 326 with AA (1, 1.5, 3 or 4 g per day) and 19 with
PXT3003 (HD). The Q and I2 indices for the random
effect models did not reveal significant heterogeneity
for CMTNS (Q-test p = 0.28; I2 = 10.9 %) nor for ONLS
(Q-test p = 0.36; I2 = 11.2 %), justifying reporting the re-
sults of the fixed effect models only.
Results obtained for CMTNS and ONLS scales were
consistent (Fig. 1a and b). After one year, CMT1A pa-
tients showed a slight deterioration under Placebo of
0.16 point in CMTNS and 0.06 point in ONLS. The
progression of patients under AA appeared stable
(−0.04 point in CMTNS and −0.01 point in ONLS) and
not significant when compared to Placebo (p = 0.390
for CMTNS and p = 0.387 for ONLS). Patients taking
PXT3003 showed an amelioration in both measures
(−0.68 point in CMTNS and −0.21 point in ONLS),
significant when compared to Placebo (p = 0.048 for
CMTNS and p = 0.044 for ONLS).
Discussion
The present meta-analysis supports the conclusions
made independently within each clinical trial as regards
efficacy of treatments and Placebo [10, 12, 14]. First, the
CMT1A patients of the Placebo groups from studies
conducted from 2006 to 2014 deteriorate rather slowly
compared to the estimated natural progression of 0.686
point/year in CMTNS reported by Shy and colleagues in
2008 [18]. These findings are consistent with the positive
placebo effects observed in diabetic neuropathy [19] or
patient-reported pain outcomes [20], although the fac-
tors accounting for such a difference remain unclear.
Lewis et al. [12] considered that systematic differences
between participants of the different studies may be par-
tially responsible; for instance the mean age and
CMTNS are slightly higher in the four clinical trials con-
sidered here than in the natural progression study byShy et al. [18]. Pareyson and colleagues [11] also pointed
out that the natural progression study was partly retro-
spective, and therefore might not be directly comparable
with clinical trials. Consequently, we believe that the
progression of CMTNS and ONLS under Placebo re-
ported here is more valuable than natural progression
estimates for the design of future clinical trials in
CMT1A, and less prone to sampling bias that might
occur in single independent studies.
Second, the progression of patients under different
dosages of AA appears quite stable, and does not reach
statistical significance versus Placebo. The difference be-
tween AA and Placebo is far below the order of magni-
tude expected for sample size calculation in the three
AA clinical trials. As it happens, the a posteriori power
to detect this difference as significant does not exceed
15 % (assuming an SD in CMTNS of 5, a correlation be-
tween baseline and final values of 0.8, and an ANCOVA
analysis at a two-sided 5 % level). In this context, de-
signing a confirmatory Phase 3 study for a treatment
showing such stabilization in CMT1A would require a
much larger sample size and longer study duration,
making it clearly unrealizable. It confirms the idea that
an effective treatment for this disease should bring an
improvement, rather than the mere ability to slow or
stabilize the disease progression [12, 14]. Even if this
effect seems quite marginal, a standardized re-analysis of
all AA patient-level data would be of great interest.
Lastly, this meta-analysis supports an improvement in
both CMTNS and ONLS with PXT3003 treatment, sta-
tistically significant when compared to Placebo. This im-
provement could herald an early, meaningful change in
the disease course.
Conducting a meta-analysis of clinical trials in
CMT1A is challenging because of the small number of
studies and of the heterogeneity of study protocols in
terms of recruitment criteria, study duration, balance of
groups, and statistical analysis. In addition, our study
evaluates CMTNS in a context where a second version
(CMTNSv2) has been proposed to reduce floor/ceiling
effects and eventually to improve the scale’s sensitivity
to change [21]. The current version of the CMTNSv2
has also been questioned recently through a Rasch ana-
lysis by Sadjadi et al. [22] and a ‘weighted’ alternative
has been suggested. In parallel, Mannil et al. [23] pro-
posed a CMTNSMod by adding three functional mea-
sures (9-hole peg test, foot dorsiflexion and walk test)
while removing Ulnar SNAP, Pin Sensibility, Vibration
and Strength of Arms. None of these modified versions
has been evaluated yet in natural history or therapeutic
trials. Despite these limitations, the present study pro-
vides a set of relevant observations, consistently ob-
tained on both CMTNS and ONLS, to be used for the




Fig. 1 Results of the meta-analysis on the change from baseline after one year. Fixed-effect meta-analysis, with treatment as moderator variable.
Difference in changes from baseline between Placebo, AA and PXT3003 were assessed through contrast tests. a Change from baseline in CMTNS
under Placebo, AA and PXT3003; b Change from baseline in ONLS under Placebo, AA and PXT3003. *p < 0.05; NS = not-significant
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PubMed MEDLINE Search Strategy
randomized controlled trial [Title/Abstract] OR controlled
clinical trial [Title/Abstract] OR placebo-controlled clin-
ical trial [Title/Abstract] OR clinical trial [Title/Abstract]
OR randomized clinical trials [mh] OR clinical trials [mh]
OR random allocation [mh] OR double-blind [mh] OR
double blind[mh] OR ((singl* [tw] OR doubl* [tw] OR
trebl* [tw] OR tripl* [tw]) AND (mask* [tw] OR blind*
[tw])) OR (placebos [mh] OR placebo* [tw] OR random*
[tw] OR follow-up study [mh] OR prospective study
[mh])) NOT (animals [mh] NOT human [mh])
AND ((Charcot-Marie-Tooth [Title/Abstract] OR
CMT [Title/Abstract] OR hmsn [Title/Abstract] OR her-
editary motor and sensory neuropathy [Title/Abstract]
OR peroneal muscular atrophy [Title/Abstract]) AND
(1A [Title/Abstract] OR type 1A [Title/Abstract]))
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